Generic placeholder image

Current Neuropharmacology


ISSN (Print): 1570-159X
ISSN (Online): 1875-6190

Peripheral Neuropathy Induced by Paclitaxel: Recent Insights and Future Perspectives

Author(s): Charity D. Scripture, William D. Figg and Alex Sparreboom

Volume 4, Issue 2, 2006

Page: [165 - 172] Pages: 8

DOI: 10.2174/157015906776359568

Price: $65


Paclitaxel is an antineoplastic agent derived from the bark of the western yew, Taxus brevifolia, with a broad spectrum of activity. Because paclitaxel promotes microtubule assembly, neurotoxicity is one of its side effects. Clinical use of paclitaxel has led to peripheral neuropathy and this has been demonstrated to be dependent upon the dose administered, the duration of the infusion, and the schedule of administration. Vehicles in the drug formulation, for example Cremophor in Taxol®, have been investigated for their potential to induce peripheral neuropathy. A variety of neuroprotective agents have been tested in animal and clinical studies to prevent paclitaxel neurotoxicity. Recently, novel paclitaxel formulations have been developed to minimize toxicities. This review focuses on recent advances in the etiology of paclitaxel-mediated peripheral neurotoxicity, and discusses current and ongoing strategies for amelioration of this side effect.

Keywords: Taxol, cremophor, ABI-007, peripheral neuropathy

« Previous

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy